The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An evaluation of FDG-PET as a predictor of metabolic response to chemotherapy in metastatic colorectal cancer patients (mCRC).
N. Van Damme
No relevant relationships to disclose
S. De Bruyne
No relevant relationships to disclose
J. Mertens
No relevant relationships to disclose
C. Van de Wiele
No relevant relationships to disclose
W. P. Ceelen
No relevant relationships to disclose
P. Smeets
No relevant relationships to disclose
L. Ferdinande
No relevant relationships to disclose
S. Laurent
No relevant relationships to disclose
K. Geboes
No relevant relationships to disclose
M. Peeters
Research Funding - Roche